MARKET

MGNX

MGNX

Macrogenics Inc
NASDAQ
4.720
+0.460
+10.80%
Opening 13:47 05/22 EDT
OPEN
4.210
PREV CLOSE
4.260
HIGH
4.770
LOW
4.205
VOLUME
1.33M
TURNOVER
0
52 WEEK HIGH
21.88
52 WEEK LOW
3.140
MARKET CAP
295.63M
P/E (TTM)
-12.5733
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at MGNX last week (0513-0517)?
Weekly Report · 2d ago
U.S. RESEARCH ROUNDUP-Arista Networks, Crescent Energy, Dell Technologies
Wall Street securities analysts revise ratings and price targets on several companies. Arista Networks, Crescent Energy and Dell Technologies among those revised on Monday. Evercore ISI raises target price to $340 from $320 for Arista. Analog Devices, Dell Technologies and Applied Materials also raise their targets.
Reuters · 2d ago
Analysts Offer Insights on Healthcare Companies: MacroGenics (MGNX) and Bruker (BRKR)
Analysts maintain Buy ratings on MacroGenics (MGNX – Research Report) and Bruker. Citi analyst Yigal Nochomovitz maintained a Buy rating on the Healthcare sector stock. Bruker has a Moderate Buy consensus price target of $ in a report released yesterday.
TipRanks · 4d ago
APP, MGNX and CYCC among pre-market losers
On the Move APP, MGNX and CYCC among pre-market losers. Augmedix (AUGX) -38% reports Q1 results. Inotiv (NOTV) will report fiscal 2024 second quarter financial results on May 15, 2024.
Seeking Alpha · 05/14 12:25
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), MacroGenics (MGNX) and Alkermes (ALKS)
TipRanks · 05/14 12:20
FFIE, OGEN and CCLD among mid-day movers
On the Move FFIE, OGEN and CCLD among mid-day movers. CareCloud (CCLD) and Gamestop Corporation (GME) Gainers: CareCloud, Novavax and Tupperware Brands Corporation. Losers: TransCode Therapeutics and Koss Corp.
Seeking Alpha · 05/13 17:30
Stocks with more than 10% short interest - Finviz Screener
Seeking Alpha · 05/13 17:07
Macrogenics Is Maintained at Neutral by HC Wainwright & Co.
Dow Jones · 05/13 16:35
More
About MGNX
MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. It is also developing various other programs.

Webull offers MacroGenics Inc stock information, including NASDAQ: MGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MGNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MGNX stock methods without spending real money on the virtual paper trading platform.